Clinical Trial Update: A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis [Phase 3]

View source ↗

Summary

Phase 3 study assessing safety and efficacy of pimavanserin in Parkinson's disease psychosis completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease
• Parkinson Disease Psychosis

Drugs mentioned

• Pimavanserin (pimavanserin)

Snippet

Sponsor: ACADIA Pharmaceuticals Inc. | Conditions: Parkinson's Disease Psychosis | Phase 3 | Status: COMPLETED | Results posted: 2014-09-09